The historical rank and industry rank for Creo Medical Group's Pretax Margin % or its related term are showing as below:
CMEOF'
s Pretax Margin % Range Over the Past 10 Years
Min: -143192.31 Med: -291.67 Max: -113.6
Current: -291.67
CMEOF's Pretax Margin % is ranked worse than 88.63% of 818
companies
in the Medical Devices & Instruments industry
Industry Median: 2.505
vs CMEOF: -291.67
Creo Medical Group (OTCPK:CMEOF) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Creo Medical Group Pretax Margin % Related Terms
Creo Medical Group Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Creo Medical Group's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CMEOF vs ABT, SYK, MDT: Pretax Margin % Comparison
For the Medical Devices subindustry, Creo Medical Group's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creo Medical Group Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Creo Medical Group's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creo Medical Group (CMEOF) has a Pretax Margin % of -884.21% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Creo Medical Group and its competitors. According to the industry distribution chart, Creo Medical Group ranks #725 out of 818 companies in the Medical Devices & Instruments industry, placing it in the top 88.6%.
Is Creo Medical Group's Pretax Margin % too high?
Creo Medical Group's current Pretax Margin % is -884.21%. Based on the distribution chart, Creo Medical Group ranks #725 out of 818 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Creo Medical Group has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's Pretax Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Creo Medical Group ranks #725 out of 818 companies for Pretax Margin %. This places Creo Medical Group in the lower half of its industry. The industry median Pretax Margin % is 2.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.51, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Creo Medical Group and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creo Medical Group's current Pretax Margin % is -884.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Creo Medical Group (CMEOF) has a current Pretax Margin % of -884.21%. The stock's GF Value™ is $0.25, compared to a current price of $0.20 — trading 20% below its estimated fair value. The current Pretax Margin % is -884.21%. Creo Medical Group's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current Pretax Margin % is -884.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creo Medical Group (CMEOF) Overvalued in 2026?
Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued.
The current stock price of $0.20 is trading 20% below its estimated GF Value™ of $0.25.
Key valuation signals for CMEOF:
Pretax Margin %: -884.21%
GF Value™: $0.25 vs. price of $0.20 (20% below fair value)
No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
53GF Score
Get the complete analysis for CMEOF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMEOF has been successfully added to your 
